Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Sanofi 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Sanofi 3Q

Genzyme revenues staunch patent losses

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi
 
3Q Revenues: $11.6 billion (-3%)

3Q Earnings: $2.1 billion (-23%)

YTD Revenues: $34.0 billion (+6%)

YTD Earnings: $6.0 billion (+6%)

Comments: Sales lost to generic competition were $576.0 million in the quarter, primarily due to generic competition for Eloxatin in the U.S. Lantus sales were up 21% to $1.6 billion, driven by U.S. sales (+22%) and Emerging Markets (+32%). New Genzyme sales were up 23%, driven by the Fabrazyme recovery. Vaccines sales were $1.9 billion (+1%). The impact of the Plavix and Avapro loss of exclusivity in the U.S. was $602.9 million at CER.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters